Moderna stock rises 6% despite GSK advancing rival mRNA flu vaccine to Phase III trials.
Moderna's stock jumped 6% even as GSK moved its mRNA-based flu vaccine into Phase III trials, signaling strong confidence in mRNA technology beyond direct competition. GSK's vaccine showed promising immune responses in mid-stage trials and targets bo...
